In a report on its website, research firm Glaucus Research Group alleged that China Medical’s CEO “orchestrated an acquisition to embezzle roughly $20-$23 million from the public company.” The firm disclosed that it held a short position in China Medical shares and stood to gain from a decline in the stock’s price.